Description: GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Wondering if GE HealthCare Technologies is trading at a bargain, or if the price has already run ahead of what it's really worth? You're not alone, and we're about to take a closer look at what the numbers suggest. GE HealthCare shares are up an impressive 11.5% in just the past week, with a modest 2.9% rise in the last month. However, they are still down about 2.7% over the past year. Recent news headlines have highlighted the company's leadership in medical imaging and ongoing partnerships...

Description: Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index easing 0.1%

Description: Health care stocks were mixed Wednesday afternoon, with the NYSE Health Care Index up 0.1% and the H

Description: GE HealthCare unveils Genesis Radiology Workspace, aiming to streamline imaging workflows and boost diagnostic precision.

Description: CHICAGO, November 26, 2025--GE HealthCare (Nasdaq: GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness.

Description: Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Description: CHICAGO, November 25, 2025--GE HealthCare (Nasdaq: GEHC) announced the introduction of Genesis™ Radiology Workspace, a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. At the center of this innovation is Genesis™ View, 510(k) pending2, a powerful new viewer designed to be a fast diagnostic, zero-footprint viewer – streamlining radiology workflows with the intent to enhance patient care whi

Description: CHICAGO, November 24, 2025--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026.

Description: Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the H

Description: The "new" GE Aerospace is not the old General Electric, and that's good news for investors.

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car

Description: GEHC's $2.3B Intelerad deal aims to accelerate cloud imaging growth, expand outpatient reach and boost its shift toward high-margin SaaS revenue.

Description: CHICAGO, November 24, 2025--GE HealthCare today announced the submission of a 510(k) to the U.S. FDA seeking clearance for Photonova™ Spectra,i its new photon-counting computed tomography (PCCT) system with advanced AI algorithmsii – marking a major milestone in the company’s decades-long history of CT innovation. Built on GE HealthCare’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver remarkable spectral and spatial resolution for ultra-high-definition (UH

Description: The consensus analyst price target for GE HealthCare Technologies stock has seen a modest increase, rising from $86.96 to $89.21. Recent analyst commentary points to a blend of market optimism and cautious sentiment. Bullish voices point to strong demand, solid execution, and innovation potential, while bears highlight ongoing regulatory and pricing headwinds. Stay tuned to learn how you can keep up with shifts in the narrative as analysts refine their expectations for this evolving...

Description: Thursday, GE Healthcare announced an agreement to acquire Intelerad, a medical imaging software provider for $2.3 billion in cash.

Description: GE HealthCare forecast Intelerad’s revenue to be approximately $270 million in the first full year of ownership. The deal expands GE HealthCare’s presence in more outpatient settings.

Description: Completion of the transaction is expected in H1 2026.

Description: Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

Description: GE HealthCare is buying medical imaging software provider Intelerad so it can further expand into outpatient and ambulatory care settings.

Description: CHICAGO, November 20, 2025--GE HealthCare (Nasdaq: GEHC) announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.

Description: Volta Medical, committed to revolutionizing care for underserved complex AF patients with breakthrough artificial intelligence (AI) solutions, has launched the first U.S. electrophysiology software developed through its strategic Joint Development Agreement with GE HealthCare.

Description: ARLINGTON HEIGHTS, Ill., November 17, 2025--GE HealthCare announces Flyrcado milestone: Strong pilot results drive broader rollout at CVAUSA

Description: CHICAGO, November 16, 2025--GE HealthCare (Nasdaq: GEHC) management will present at the following upcoming investor conference.

Description: GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best digital health stocks to buy now. Wall Street’s sentiment on GE HealthCare has remained active in recent weeks, with analysts from several firms adjusting their targets as of late October. On October 30, 2025, Morgan Stanley raised its price target on GE HealthCare from $74 […]

Description: Amneal Pharmaceuticals announced that the U.S. FDA has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque, with plans to launch in the first quarter of 2026 for use in multiple imaging procedures. This marks a significant entry into a US$652 million market and expands Amneal's offering of complex injectable pharmaceuticals, targeting both adult and pediatric patient populations. We'll explore how FDA approval of Amneal's first-to-market...

Description: GE HealthCare Technologies (GEHC) has recently caught the attention of market watchers following a period of moderate stock price movement. With the shares ending at $73.97, investors are considering the company’s recent growth trends and outlook. See our latest analysis for GE HealthCare Technologies. GE HealthCare Technologies’ share price has drifted lower so far this year, reflecting shifting market sentiment after a solid multi-year run. While the 1-month share price return stands at a...

Description: First-to-market complex injectable with expected launch in Q1 2026BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare’s Omnipaque® (iohexol) injection. Amneal expects to launch the product in the first quarter of 2026. Iohexol is a radiographic contrast agent

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: DeepHealth TechLive Command Center DeepHealth TechLive Command Center Radiologist reading mammogram with DeepHealth's Breast Suite Radiologist reading mammogram with DeepHealth's Breast Suite AI-enabled lesion localization and suspicion score Sonographer using DeepHealth Thyroid Suite Sonographer using DeepHealth Thyroid Suite Collaboration aims to expand existing U.S. relationship combining GE HealthCare’s mammography systems with DeepHealth’s Breast Suite to include a worldwide distribution ar

Description: Investing.com -- Morgan Stanley made several notable adjustments to its U.S. All Cap Growth model portfolio, increasing exposure to semiconductors and software while exiting positions in healthcare and restaurants.

Description: GE HealthCare Technologies Inc. reported its third-quarter and nine-month 2025 earnings, with revenue rising to US$5.14 billion and US$14.93 billion, respectively, while net income for the quarter declined to US$446 million from the previous year. The company reaffirmed its full-year 2025 organic revenue growth target despite ongoing concerns around trade pressures and margin challenges. We'll explore how the reaffirmed annual growth guidance in the face of trade challenges may shape GE...

Description: Although GE HealthCare stock has lagged behind the broader market over the past year, analysts remain moderately bullish about its prospects.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: GE HealthCare’s third quarter saw revenue and adjusted profit come in slightly above Wall Street’s expectations, but the market reacted negatively, reflecting concerns about margin pressures. Management pointed to strong demand across imaging and pharmaceutical diagnostics as primary drivers, with robust orders growth and new enterprise deals contributing to a healthy backlog. However, increased tariffs and a product hold in Patient Care Solutions weighed on profitability. CEO Peter Arduini note

Description: CHICAGO, November 03, 2025--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference.

Description: GE HealthCare Technologies Inc. ( NASDAQ:GEHC ) shareholders are probably feeling a little disappointed, since its...

Description: GE HealthCare Technologies (GEHC) posted a net profit margin of 10.9%, a notable improvement from 8.6% a year ago. This was supported by a 32.3% surge in earnings over the past year, which far outpaces its five-year average annual earnings growth of just 0.06%. With revenue projected to grow at 4.1% per year and earnings at 5.6% per year, both figures are trailing broader US market forecasts. Despite this, the company is still being recognized for the high quality of its earnings and a...

Description: Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 22.6% climb.

Description: GE HealthCare Technologies Inc (GEHC) reports a 4% organic revenue growth, strategic partnerships, and raised EPS guidance despite tariff impacts and segment challenges.

Description: GEHC vs. ESLOY: Which Stock Is the Better Value Option?

Description: GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best up and coming stocks to buy right now. On October 13, BTIG analyst Ryan Zimmerman raised the firm’s price target on GE HealthCare to $89 from $87 and kept a Buy rating on the shares, which came as part of BTIG’s broader research note previewing […]

Description: Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 5.8% year on year to $5.14 billion. Its non-GAAP profit of $1.07 per share was 2.2% above analysts’ consensus estimates.

Description: GE HealthCare reported third-quarter earnings per share of $1.07 from sales of $5.1 billion. Wall Street was looking for EPS of $1.05 from sales of $5.1 billion.

Description: GE HealthCare’s biggest revenue rises were a 7% uplift in its advanced visualisation solutions business and a 20% rise in pharmaceutical diagnostics.

Description: Peter J. Arduini: We delivered another quarter of solid results, and we're focused on executing our precision care strategy. For instance, we're seeing robust growth in contrast media and nuclear medicine, where we're uniquely positioned to deliver end-to-end solutions for our customers. Earlier this month, we announced a fourteen-year care alliance with UC San Diego Health focused on early detection and advancing cancer care with imaging solutions and novel therapies such as theranostics.

Description: The headline numbers for GE HealthCare (GEHC) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: GE HealthCare Technologies’ said profit fell in the third quarter, weighed down by the added costs of tariffs.

Description: GE HealthCare (GEHC) delivered earnings and revenue surprises of +1.90% and +1.48%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: The main US stock measures were pointing higher in Wednesday's premarket activity as traders await t

Description: Investing.com -- GE HealthCare reported third-quarter earnings broadly in line with expectations and raised the lower end of its full-year profit outlook.

Description: Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 5.8% year on year to $5.14 billion. Its non-GAAP profit of $1.07 per share was 2.2% above analysts’ consensus estimates.

Description: On a per-share basis, the Chicago-based company said it had net income of 98 cents. Earnings, adjusted for one-time gains and costs, came to $1.07 per share. The results surpassed Wall Street expectations.

Description: CHICAGO, October 29, 2025--GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2025.

Description: Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.

Description: GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.

Description: TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.

Description: In recent weeks, partnerships between GE HealthCare and major U.S. health systems, along with multiple new product launches and regulatory clearances, have signaled expanded momentum in hospital AI, ultrasound, and patient monitoring. An interesting development is the customer-driven approach behind the AI hospital operations solutions, with frontline clinicians from Duke Health and The Queen’s Health Systems directly informing application design. We'll explore how these AI-driven clinical...

Description: GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.

Description: Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "GE HealthCare Technologies Inc (GEHC) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. GE HealthCare's offerings encompass products and services for drug discovery, biopharmaceutical manufacturing, cellular technologies, imaging agents for medical scanning, and comprehensive healthcare IT solutions. Additionally, GE HealthCare provides services like performance improvement, computerized data management,

Description: CHICAGO, October 21, 2025--GE HealthCare (Nasdaq: GEHC) today announced it has received CE mark for its Carevance™ patient monitor, advancing accessible and reliable care for more customers starting in Europe. Built on GE HealthCare’s clinical excellence, Carevance offers a clinically reliable and cost-effective solution with validated parameters and an intuitive, efficient workflow that can help empower care teams to stay focused on their patients. Hospitals today are facing new challenges, fro

Description: CHICAGO, October 20, 2025--GE HealthCare (Nasdaq: GEHC) today announced collaborations with two leading U.S. health systems—The Queen’s Health Systems in Honolulu, HI and Duke Health in Durham, NC—to help advance the development of GE HealthCare’s new AI-driven hospital operations software. Both health systems plan to contribute their frontline expertise to inform GE HealthCare’s forthcoming cloud-first Software as a Service solution that will be part of GE HealthCare’s CareIntellect family of a